This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Two interventions were assessed within a clinical trial: sertraline and mirtazapine. The comparator was placebo. All participants received normal care. The target doses were 150mg sertraline or 45mg mirtazapine daily, with titration over eight weeks; according to the clinician's adjustments.
Location/setting
UK/hospital and community.
Methods

Analytical approach:
An economic analysis was conducted alongside a pragmatic, multicentre, randomised placebo-controlled trial of 339 patients. Cost-effectiveness and cost-utility were analysed over 13 weeks, and 39 weeks. Bootstrapping was used for each analysis. The authors stated that two perspectives were adopted: that of the health and social care agencies; and that of the health and social care agencies and unpaid carers.
Effectiveness data:
The primary effectiveness outcome was the reduction in depression, measured on the Cornell Scale for Depression in Dementia (CSDD). Patients were diagnosed with dementia of the Alzheimer's type according to the National Institute of Neurological and Communicative Disorders and Stroke, and the Disease and Related Disorders criteria. Patients initially had a score of more than seven on the CSDD; higher scores were associated with a worse outcome. The CSDD score was measured at 13 weeks and at 39 weeks. Analyses were conducted using intention to treat. A clinical trials unit independently allocated patients to treatment.
Monetary benefit and utility valuations:
The utility values were derived using EQ-5D scores, from the trial participants, which were valued using UK population data.
Measure of benefit:
The measures of benefit were quality-adjusted life-years (QALYs), and improvement (reduction) in CSDD score.
